

### **REMARKS**

Claims 19-39 have been cancelled and new claims 40-49 presented. Support for the new claims can be found throughout applicant's specification.

#### **Claim Rejection - 35 USC § 112**

Rejection of Claims 31-33 for prevention of scars is now moot in view of the new claims presented.

#### **Claim Rejection - 35 USC § 112**

Applicant has now replaced "suitable dosage forms" with "pharmaceutically acceptable dosage forms" in the proposed new claims.

#### **Claim Rejection - 35 USC § 102**

The rejection of the claims over the '037 reference should now be withdrawn since no magnesium compounds for treating acne are included in new claims.

The rejection of the claims over the '630 reference for treating acne should be withdrawn. Since '630 only refers to the specific chelates of aluminum chloride and aluminum zinc sulfate with cysteic acid or its analogues, the above cited aluminum compounds are excluded in new Claim 40. Only four aluminum salts are now specifically claimed because of applicant's experience in past years.

For a similar reason described above, only the same four specific aluminum salts are now claimed in Claim 46 and Claim 47 for treating warts and in Claim 40 for treating acne. Thus, the rejection over the '339 reference should be withdrawn.

The cited teaching of '107 against the use of magnesium compounds for treating warts is acknowledged. Thus, no magnesium compounds are claimed for treating warts in Claim 46 and Claim 47.

The rejection of certain claims over '790 for treating rosacea is obviated. For reasons discussed above, only four aluminum salts are retained in Claim 42 for treating rosacea and in Claim 40 for treating acne.

The teaching of '556 for using magnesium salts to treat rosacea is also acknowledged. Since no one has claimed the use of bismuth compounds in treating rosacea, use of selected bismuth compounds for treating rosacea is now retained in Claim 44. Please note that applicant has employed a bismuth compound in treating rosacea.

With regard to the '784 reference in rejecting certain claims, no bismuth compounds are claimed for treating acne in the new claim. Thus, the rejection should be withdrawn.

In view of the present amendment, it is respectfully submitted that all of the rejections under 35 U.S.C. 102 should be withdrawn.

In view of the above amendment and remarks, Applicant respectfully requests a Notice of Allowance. If the Examiner believes a telephone conference would advance the prosecution of this application, the Examiner is invited to telephone the undersigned at the below-listed telephone number.

Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

Date: March 26, 2007

**23552**

PATENT TRADEMARK OFFICE



Ronald A. Daignault, Ph.D.  
Of Counsel  
Reg. No. 25,968